Oncotelic Therapeutics Files 8-K

Ticker: OTLC · Form: 8-K · Filed: Oct 22, 2025 · CIK: 908259

Oncotelic Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyOncotelic Therapeutics, Inc. (OTLC)
Form Type8-K
Filed DateOct 22, 2025
Risk Levellow
Pages3
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Oncotelic filed an 8-K on 10/21/25 for other events and financials.

AI Summary

On October 21, 2025, Oncotelic Therapeutics, Inc. filed an 8-K report. The filing indicates the company is reporting on "Other Events" and "Financial Statements and Exhibits." No specific details regarding these events or financial statements are provided in the excerpt.

Why It Matters

This filing signals that Oncotelic Therapeutics has made a significant update or event disclosure to the SEC, requiring investor attention.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate financial or operational news.

Key Players & Entities

  • Oncotelic Therapeutics, Inc. (company) — Registrant
  • October 21, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 000-21990 (filing_id) — SEC File Number
  • 13-3679168 (ein) — IRS Employer Identification No.
  • 29397 Agoura Road, Suite 107 (address) — Principal executive offices
  • Agoura Hills, CA 91301 (address) — Principal executive offices

FAQ

What specific "Other Events" are being reported by Oncotelic Therapeutics, Inc. in this 8-K filing?

The provided excerpt does not specify the details of the "Other Events" being reported.

What is the nature of the "Financial Statements and Exhibits" being filed?

The excerpt does not provide details on the content of the financial statements or exhibits.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on October 21, 2025.

In which state is Oncotelic Therapeutics, Inc. incorporated?

Oncotelic Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Oncotelic Therapeutics, Inc.?

The principal executive office is located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301.

Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2025-10-22 09:00:58

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2025 ONCOTELIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-21990 13-3679168 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 29397 Agoura Road , Suite 107 Agoura Hills , CA 91301 (Address of principal executive offices and Zip Code) Registrant's telephone number, including area code ( 650 ) 635-7000 Not applicable. (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of class Trading Symbols Name of each exchange on which registered N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On October 21, 2025, Oncotelic Therapeutics, Inc. (the "Company") announced that Dr. Vuong Trieu, CEO of the Company presented an investor corporate presentation ("Corporate Presentation") at LD Micro in San Diego, California. A copy of the Corporate Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. Forward-Looking The Corporate Presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this communication, the words "will," "may," "would," "approximate," "expect," "intend," and similar expressions and their variants, as they relate to the Company, identify forward-looking statements. Forward looking statements contained in the Corporate Presentation include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration materially from those contained in any forward-looking statement as a result of various factors, including the risk factors included in the Company's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Disclaimer. The information in Section 8.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.